FDA approves three-times-a-week Copaxone
FDA approves three-times-a-week Copaxone
Teva Pharmaceutical Industries Ltd. has announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental new drug application (sNDA) for three-times-a-week Copaxone 40mg/mL, a new dose of Copaxone . This new formulation will allow for a less frequent dosing regimen administered subcutaneously for patients with relapsing forms of multiple sclerosis (MS). In addition to the newly approved dose, daily Copaxone 20 mg/mL will continue to be available. The daily subcutaneous injection was approved in 1996......... Read More - http://www.ms-uk.org/copaxone
MS-UK - http://www.ms-uk.org/
- Quest56
- Family Elder
- Posts: 323
- Joined: Mon May 22, 2006 2:00 pm
- Location: Northern Calif Monterey Bay Area
- Contact:
Re: FDA approves three-times-a-week Copaxone
Interesting. I've been using copaxone now for over 15 years, and have NO interest in moving to an every-other-day regimen.
I manage taking my own perscriptions and can't imagine how I would keep track of taking a shot every other day. Poor memory makes simple things like this quit difficult.
I'm sure I'm not alone in that respect.
I manage taking my own perscriptions and can't imagine how I would keep track of taking a shot every other day. Poor memory makes simple things like this quit difficult.
I'm sure I'm not alone in that respect.
CCSVI Procedure 9/16/2009 at Stanford
Stent in left and right IJVs
SPMS
Copaxone
Former Ampyra User
Regular Botox Bladder Injections
300mg d-Biotin / day
Stent in left and right IJVs
SPMS
Copaxone
Former Ampyra User
Regular Botox Bladder Injections
300mg d-Biotin / day
Re: FDA approves three-times-a-week Copaxone
Anyone know what the price will be for the three times a week prescription? Will insurance companies cover this new drug?
Re: FDA approves three-times-a-week Copaxone
I will be glad to switch to this if my insurance will pay. It's very likely that it will be more expensive than the every day shots, because it's new on the market.